Category Archives: R&D

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable. 

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices

By Frederick M Abbott*, IP Watch | 31/05/2017 The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. … Continue reading

Posted in Cancer, Patent, R&D, Uncategorized | Leave a comment

Lexmark: The Supreme Court’s patent exhaustion case and parallel trade in drugs

Source: Knowledge Ecology International The Supreme Court’s decision in IMPRESSION PRODUCTS, INC. v. LEXMARK INTERNATIONAL, INC.  has clarified that the United States has world wide exhaustion of patent rights.   According to Professor Fred Abbott, who knows a lot about this issue, and … Continue reading

Posted in Cancer, Delinkage, ISDS, R&D, Uncategorized, USFDA | Leave a comment

Better life through medicine—let’s leave no one behind

Source: http://www.thelancet.com The Lancet Commission on Essential Medicines Policies  rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we … Continue reading

Posted in Delinkage, R&D, R&D, Sofosbuvir, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment

Appeal from Asian Civil Society to the DG to discuss the report of United Nations Secretary-General’s High-Level Panel on Access to Medicines (HLP) at the forthcoming EB

Dr. Margaret Chan, Director-General, World Health Organization, Switzerland Dr Poonam Khetrapal Singh, Regional Director of WHO South-East Asia Region, New Delhi Dr. Raymond Busuttil, Chairman of the Executive Board, World Health Organization   18 November 2016 Re: Appeal from Asian Civil Society to … Continue reading

Posted in R&D, Uncategorized, UNHLP report | Leave a comment

The U.S. Is Standing in the Way of Cheaper Drugs for the Poor

By JASON CONE and RAYMOND C. OFFENHEISER, The New York Times|OCT. 27, 2016 Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the … Continue reading

Posted in Innovation, R&D, TPP, Uncategorized, UNHLP report, WHO | Leave a comment

Just the Medicine

How the next president can lower drug prices with the stroke of a pen. By Alicia Mundy, Washington Monthly | Nov/Dec 2016 It’s hard to watch television or read a newspaper these days without seeing stories about outrageous prescription drug … Continue reading

Posted in Bayh Dole Act, Drug prices, Patent, R&D, Uncategorized | Leave a comment